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Abstract
Background: When germline mutations are suspected as causal in cancer, patient DNA may be sequenced to
detect variants in relevant genes. If a particular mutation has not been reported in reliable family studies, genetic
counselors are facing a dilemma of appropriately informing patients. Many sequencing facilities provide an
interpretation of the findings based on the available sequence databases or on prediction tools that are curated
from bioinformatics and mechanistic datasets. The counseling dilemma is exacerbated if the pedigree data are not
informative but the in silico predictions suggest pathogenicity.
Methods: We present here a real world example of the c.256G > A CDKN2A variant, which was detected in one
melanoma patient where two siblings were diagnosed with melanoma in situ. We investigated a detailed family
history of the affected siblings in order to survey probability of the cancer risks within the context to this mutation.
Results: This c.256G > A CDKN2A variant was detected in one of the brothers and in the melanoma-free mother
while the other brother in the family tested negative. The variant had been previously described in one patient
from a melanoma family. In the family under investigation, the mother’s 16 first-and second-degree relatives had
survived past the median onset age for melanoma and none presented melanoma. We tested the variant using
multiple bioinformatic tools that all predicted deleteriousness of the variant. The genetic counseling report to the
melanoma patient stated that the CDKN2A variant was ‘likely pathogenic’ and the disease was defined as ‘likely
hereditary melanoma’.
Conclusions: The pedigree data showed at the most a low penetrance variant, which, if taken into consideration,
might have altered the provided diagnosis. When dealing with ‘practically’ unknown variants the counselors would
be advised to incorporate a detailed family history rather than basing predictions on functionality provided by
sequencing facilities.
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Introduction
A study from 2015 concluded: “Clinicians, patients and
their relatives would all benefit from an improved level
of genetic literacy” [1]. Indeed raising the genetic literacy
is a formidable challenge, for cancer alone more than
100 high risk genes are known and many of these are
tumor suppressor genes with large coding regions vul-
nerable to mutations [2, 3]. The core of the literacy
problem was exemplified by Richards et al. giving se-
quencing data on Mendelian disease testing of 5800 per-
sons; 83% of patients had variants that are rare or of
uncertain clinical significance (5776 variants) and 17% of
patients had pathogenic or “likely pathogenic” variants
seen ≥10 times (63 variants) [4]. Several expert groups
have provided recommendations for the interpretation
of DNA sequence variations in order to help molecular
diagnostics, including the American College of Medical
Genetics and Genomics and the Association for Molecu-
lar Pathology (ACMG/AMP) and the Clinical Genome
(ClinGen) [4–6]. We will illustrate the genetic literacy
problem with a real world example from a melanoma
family with a CDKN2A mutation c.256G > A.
The most common high-risk predisposing gene for cu-
taneous melanoma (subsequently melanoma) is cyclin
dependent kinase inhibitor 2A (CDKN2A) [7]. It also
predisposes to pancreatic cancer and possibly other can-
cers [2, 7]. The CDKN2A gene encodes two structurally
and functionally unrelated proteins, p16INK4a and ARF.
P16 and ARF are transcribed from two separate pro-
moters with unique first exons (exon 1α and 1β) and
shared exons 2 and 3 that are translated from alternate
reading frames and bear no amino acid homology
(Fig. 1). P16, a 156 amino acid protein, binds to cyclin
dependent kinase 4 and 6 through four ankyrin repeats
that results in inhibition of Rb phosphorylation [8, 9].
ARF, a highly basic 132 amino acid peptide, stabilizes
p53 through sequestration of MDM2 in nucleolus that
inhibits cell cycle in response to oncogenic signals. P16
and ARF have been shown to be markers of senescence
in human cells and mouse embryonic fibroblasts, re-
spectively [10]. The a CDKN2A mutation c.256G > A
causes an Ala86Thr amino acid changed in p16 and
Cys100Tyr in ARF where the nucleotide change is
c.299G > A. ClinVar database lists 537 variants for
CDKN2A and of those 43 variants are considered patho-
genic with only 6 being missense variants (http://simple-
clinvar.broadinstitute.org/). Almost all pathogenic
variants were described in syndromes including melan-
oma. However, germline mutations may also predispose
to pancreatic cancer [11].
We have been consulting a family in which one sibling
was diagnosed with invasive melanoma and two others
were diagnosed with in situ melanoma (Fig. 2). CDKN2A
mutation testing revealed a missense variant c.256G > A
in the woman with invasive melanoma (the mutation is
indicated in Fig. 1, also giving the resulting amino acid
change in ARF). Her first-degree relatives were also
tested and her mother and one of the brothers were also
positive while her father and younger brother were nega-
tive. This mutation has been described so far globally
only in one person from a melanoma family [12]. We il-
lustrate the problem of clinical counseling with gene var-
iants that lack data on segregation in cancer pedigrees.
We want to point out that taking a family history into
consideration may help the counselor to improve his
message to the patient.
Patients and methods
Family
The family was of a Finnish origin and the members
were fair-skinned and blue eyed. The affected female pa-
tient was diagnosed with a small invasive melanoma on
the leg at the age of 66 years. Her older brother was di-
agnosed 3 years before her at the age 69 with melanoma
on the back, and a younger brother was diagnosed 1 year
after her at the age of 57 on the back. Both brothers had
Fig. 1 Structure of the CDKN2A locus showing the transcription start sites of proteins p16 and ARF and the exons used. The variant of interest is
showen for p16 (on top) and ARF (below)
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melanoma in situ. DNA from expired parents was also
available for sequencing. The mothers’ family included four
older sisters all of whom survived to an old age. The sisters
had altogether 12 children with the current age range from
73 to 88 years; 6 children had died between the ages of 66 to
81 years. As half of the children were alive they were deleted
from the pedigree figure. The information about the family
history was acquired by a personal interview conducted by a
physician, who was also a member of the family.
Sequencing and counseling
Person II/2 and II/3 were diagnosed with melanoma and in
situ melanoma, respectively. As II/1, who lived aboard, was
diagnosed earlier with in situ melanoma, the consulting
dermatologists referred II/2 and II/3 to medical genetics
counseling, where samples were sent for panel sequencing
at Blue Genetics. A variant in the CDKN2A gene was de-
tected in II/2 but not in II/3. The company classified the
c.256G >A as ‘likely pathogenic’ and the consulting medical
geneticist described the condition to II/2 as ‘likely heredi-
tary melanoma’ and recommended dermatological check-
ups every 6months and a biannual pancreas cancer screen-
ing. An annual dermatological control was recommended
for II/3. Information on other risk factors, particularly on
solar irradiation was also given, and II/2 was explained that
her children may also be gene carriers.
Other family members were sequenced as part of a sci-
entific project using Sanger sequencing for CDKN2A
exon 2 specific primers as described previously [13].
Each analysis was repeated twice. The samples from II/2
and II/3 were repeated by Sanger sequencing and the re-
sults were consistent with the panel sequencing results.
In silico annotation
The variant was assessed for conservation and deleterious-
ness using different prediction tools. High evolutionary
conservation suggests functional importance of the pos-
ition. Genomic Evolutionary Rate Profiling (GERP) [14],
PhastCons [15] and PhyloP [16] were used to assess con-
servation of the variant position. Deleteriousness was pre-
dicted using the following tools: CADD v1.5 [17], SIFT
[18], PolyPhen V2-HDIV [19], PolyPhen V2-HVAR [19],
MutationTaster [20], Mutation Assessor [21], FATHMM
[22], PROVEAN [23], VEST3 [24] and RI [25]. The variant
was assessed further with SNAP2 [26], a neural network
based classifier that distinguishes between effective and
neutral variants.
Results
Mutation analysis for individuals II/2 and II/3 was done by
panels sequencing and verified by Sanger sequencing, for
other individuals only using Sanger sequencing. The muta-
tional status of the 5 family members is shown in Fig. 2.
For all positive individuals the mutation was c.256G >A
(Ala86Thr). The mother of the affected siblings died at age
of 80 years without melanoma or other known cancer, simi-
lar to her 4 sisters. Among the 12 offspring of the 4 sisters
none are known to have melanoma but one women died of
pancreatic cancer (age 76 years). None of the sisters or their
offspring (combined 16 individuals) in generation I or II
were known to have melanoma.
SNAP2 predicts functionality of amino acid changes at
various locations and in Fig. 3 we show an amino acid
segment around Ala86Thr. Almost all changed at amino
acid 86 are predicted to be deleterious, as are most other
substitutions in this segment. SNAP2 calculates a predic-
tion score for the Ala86The substitution, which is 63 out
of a maximum of 100, and the expected accuracy of the
prediction is 80%.
We applied a number prediction tools for deleterious-
ness and conservation for the c.256G > A variant
(Table 1). SIFT, PolyPhen, Mutation Taster, PROVEAN
Fig. 2 Pedigree of the family of interest. The two generations and each family member labelled. The symbols used are shown below
the bedigree
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Fig. 3 The SNAP2 tool prediction of functionality of the amino acid changes at various locations of the p16 protein approximately centered
around Ala86Thr at code 86. The color code illustrates the probability of deleteriousness
Table 1 Deleteriousness and conservation scores for the CDKN2A variant c.256G > A
Tools Score Interpretation
DELETERIOUSNESS SCORES
SIFT Deleterious (D) D – Damaging/Deleterious (> 0.05)
T – Tolerated (< 0.05)
PolyPhen-v2 PolyPhen2_HDIV = 1.000 (D)
PolyPhen2_HVAR = 0.945 (D)
D – Probably damaging (> 0.908)
P – Possibly damaging (0.446 < score≤ 0.908)
B – Benign (≤ 0.446)
MutationTaster 0.957 (D) A – Disease causing automatic
D – Disease causing (> 0.5)
N – Polymorphism (< 0.5)
P – Polymorphism automatic
MutationAssessor No data –
FATHMM No data –
VEST3 No data –
PROVEAN −3.711 (D) D – Damaging/Deleterious (≤ −2.5)
N – Neutral (> − 2.5)
Reliability Index (RI) 6 D – Damaging (≥ 5)
N – Neutral (< 5)
CADD v1.5 33 CADD > 10 = In top 10%,
CADD > 20 = In top 1%,
CADD > 30 = In top 0.1% of probable deleterious variants in the human genome
CONSERVATION SCORES
GerpN 5.93 Highly conserved (> 2)
PhastCons 0.999 Highly conserved (> 0.3)
PhyloP 5.697 Highly conserved (> 3.0)
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and Reliability Index uniformly predict deleteriousness.
CADD score of 33 is high. The locus is highly
conserved.
Discussion
High-risk CDKN2A mutations significantly contribute to
the genetic architecture of melanoma as these are found
in about 30% of patients in families of three or more af-
fected individuals [27]. According to a Swedish study,
CDKN2A positive families accounted for 11.5% (31/269)
of all melanoma families, and the positivity correlated with
the number of affected individuals; in the positive families
a median of 6 individuals melanomas were diagnosed
compared to 2 individuals in mutation negative families
[28]. However, we have earlier shown that in the Swedish
population families of 3 or more diagnosed melanoma
cases accounted for less than 8% of familial melanoma
[29]. Thus the present sibship of 3 affected cases is rare;
however, it may be noted that the brothers had only mel-
anoma in situ. Family studies have shown that the melan-
oma in situ show approximately an equal familial risk of
about 2.5–3.0 as does invasive melanoma [30, 31].
It is known that life-time risk (penetrance) of melanoma
in carriers of CDKN2A mutations may be modified by
other genetic and environmental factors [7]. Solar radi-
ation is a likely environmental factor which was invoked
as an explanation why penetrance of CDKN2A mutations
in high-risk families is higher in Australia than in Europe
[27]. However, a later study did not find difference in
penetrance and considered the contribution of ambient
solar radiation unlikely [32]. The population-based pene-
trance of CDKN2A mutations has been estimated to be
14% by age 50 years and 28% by age 80 years based on
Australian and North American populations [33].
The detected mutation caused a change in two pro-
teins, p16 and ARF, and it is not possible to assign the
effects, if any, to one or the other, even though much of
the global literature concerns p16. Our in silico analysis
of the detected variant using the various prediction tools
suggested overwhelmingly genetic consequences, but we
do not know how the ‘likely pathogenic’ classification by
Blue Genetics was derived at. This is, however, contra-
dicted by the overwhelming pedigree data. Firstly, one of
the affected brothers was negative and the mother with
mutation was melanoma-free until her death at age 80
years. Secondly, the mother’s 4 sisters and their 12 off-
spring were melanoma-free into an advanced age, well
past the median age of melanoma diagnosis (64 years)
[34]. As it can be assumed that 50% of the 4 sisters and
25% of their offspring were mutation carriers the pene-
trance of the mutation is low. Of course, de novo muta-
tion cannot be excluded. However one person was
diagnosed with pancreatic cancer but at a relatively ad-
vanced age of 76 years. Factors other than CDKN2A
mutations may have contributed to melanoma risk. Family
members share skin types and many habits. The affected 3
siblings were fair-skinned and were not protected against
sun bathing in their youth. They reported several sun
burning episodes during early summers.
In summary, without pedigree data it is justified to con-
sider CDKN2A c.256G >A mutations likely pathogenic.
However, the available pedigree data in this case suggest
that the penetrance is low but that does not entirely ex-
clude a low level of pathogenicity. To avoid unnecessary
fear, genetic counseling should collect a detailed family
history, and use such information to modify the advice to
patients and their relatives. All patients have families and
the majority would be highly motivated to collaborate
with the counsellors. As this case demonstrates, a genetic
change alone is not sufficient to tell the proband or family
members how high the risk of melanoma(s) is in their
family or even mutation carriers. A family history, and
perhaps an investigation into behavior, such as sunbathing
in this case, would help the geneticist to assess the pene-
trance of the mutation found. In essence, the penetration
of a mutation is the combined outcome of genetic modify-
ing factors together with behavioral factors.
Ethical statement
Genetic testing was approved by the ethical board of the
Instituto Valenciano de Oncologia, Valencia, Spain. Two
of the patients underwent clinical genetic counseling at
the University Hospital in Tampere, Finland. The living
individuals gave an informed consent for mutation testing.
Acknowledgements
Not applicable.
Authors’ contributions
K.H. had full access to all of the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis. Study
concept and design: K.H. Acquisition, analysis, or interpretation of data: All
authors. Drafting of the manuscript: K.H., A. S, A.H., R.K. Critical revision of the
manuscript for important intellectual content: All authors. Final approval of
the manuscript for publication: All authors.
Funding
This study was supported by the European Union’s Horizon 2020 research
and innovation programme, grant No 856620, Jane and Aatos Erkko
Foundation, HUCH Research Funds (EVO), Sigrid Juselius Foundation, Finnish
Cancer Organizations, University of Helsinki, The Finnish Society of Sciences
And Letters. Open access funding provided by Projekt DEAL.
Availability of data and materials
Panel sequencing data are not available because it was ordered by the
hospital from a private sequencing company. All other data are available
upon request.
Consent for publication
Not applicable.
Competing interests
A.H. is a shareholder in Targovax ASA. A.H. is an employee and shareholder
in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest.
Hemminki et al. Hereditary Cancer in Clinical Practice           (2020) 18:15 Page 5 of 6
Author details
1Division of Molecular Genetic Epidemiology, German Cancer Research
Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany.
2Cancer Epidemiology, German Cancer Research Center, D-69120 Heidelberg,
Germany. 3Faculty of Medicine and Biomedical Center in Pilsen, Charles
University in Prague, 30605 Pilsen, Czech Republic. 4Hopp Children’s Cancer
Center (KiTZ), Heidelberg, Germany. 5Division of Pediatric Neurooncology,
German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK),
Heidelberg, Germany. 6Division of Functional Genome Analysis (B070),
German Cancer Research Center (DKFZ), Heidelberg, Germany. 7Department
of Dermatology, Instituto Valenciano de Oncología, València, Spain. 8School
of Medicine, Universidad Católica de Valencia San Vicente Mártir, València,
Spain. 9Cancer Gene Therapy Group, Translational Immunology Research
Program, University of Helsinki, Helsinki, Finland. 10Comprehensive Cancer
Center, Helsinki University Hospital, Helsinki, Finland.
Received: 2 May 2020 Accepted: 21 July 2020
References
1. Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB,
et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for
managing variants of uncertain clinical significance. Ann Oncol. 2015;26(10):
2057–65.
2. Rahman N. Realizing the promise of cancer predisposition genes. Nature.
2014;505:302–8.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW.
Cancer genome landscapes. Science. 2013;339(6127):1546–58.
4. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet Med. 2015;
17(5):405–24.
5. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al.
ClinGen--the clinical genome resource. N Engl J Med. 2015;372(23):2235–42.
6. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al.
Standards and guidelines for the interpretation and reporting of sequence
variants in Cancer: a joint consensus recommendation of the Association for
Molecular Pathology, American Society of Clinical Oncology, and College of
American Pathologists. J Mol Diagn. 2017;19(1):4–23.
7. Read J, Wadt KA, Hayward NK. Melanoma genetics. J Med Genet. 2016;53(1):1–14.
8. Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K. Selective deletion of
exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes
Chromosomes Cancer. 1998;23(3):273–7.
9. Kumar R, Smeds J, Lundh Rozell B, Hemminki K. Loss of heterozygosity at
chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and
mutations in the p16 and p14ARF genes in sporadic primary melanomas.
Melanoma Res. 1999;9(2):138–47.
10. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev
Cancer. 2015;15(7):397–408.
11. Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43(5):548–53.
12. Bruno W, Ghiorzo P, Battistuzzi L, Ascierto PA, Barile M, Gargiulo S, et al.
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J
Am Acad Dermatol. 2009;61(5):775–82.
13. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic
alterations in the melanoma genome: a high-resolution array-based comparative
genomic hybridization study. Genes Chromosomes Cancer. 2010;49(8):733–45.
14. Cooper GM, Stone EA, Asimenos G, Program NCS, Green ED, Batzoglou S,
et al. Distribution and intensity of constraint in mammalian genomic
sequence. Genome Res. 2005;15(7):901–13.
15. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al.
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast
genomes. Genome Res. 2005;15(8):1034–50.
16. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral
substitution rates on mammalian phylogenies. Genome Res. 2010;20(1):110–21.
17. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
framework for estimating the relative pathogenicity of human genetic
variants. Nat Genet. 2014;46(3):310–5.
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat
Protoc. 2009;4(7):1073–81.
19. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human
missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;
Chapter 7(Unit7):20.
20. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods. 2014;11:361.
21. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein
mutations: application to cancer genomics. Nucleic Acids Res. 2011;39(17):e118-e.
22. Shihab HA, Gough J, Cooper DN, Day IN, Gaunt TR. Predicting the
functional consequences of cancer-associated amino acid substitutions.
Bioinformatics. 2013;29(12):1504–10.
23. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional
effect of amino acid substitutions and Indels. PLoS One. 2012;7(10):e46688.
24. Carter H, Douville C, Stenson PD, Cooper DN, Karchin R. Identifying
Mendelian disease genes with the variant effect scoring tool. BMC
Genomics. 2013;14(Suppl 3):S3.
25. López-Ferrando V, Gazzo A, de la Cruz X, Orozco M, Gelpí JL. PMut: a web-
based tool for the annotation of pathological variants on proteins, 2017
update. Nucleic Acids Res. 2017;45(W1):W222–W8.
26. Hecht M, Bromberg Y, Rost B. Better prediction of functional effects for
sequence variants. BMC Genomics. 2015;16(8):S1.
27. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT,
et al. Features associated with germline CDKN2A mutations: a GenoMEL
study of melanoma-prone families from three continents. J Med Genet.
2007;44(2):99–106.
28. Helgadottir H, Hoiom V, Tuominen R, Nielsen K, Jonsson G, Olsson H, et al.
Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
J Natl Cancer Inst. 2016;108(11)..
29. Frank C, Sundquist J, Hemminki A, Hemminki K. Risk of other cancers in
families with melanoma: novel familial links. Sci Rep. 2017;7:42601.
30. Chen T, Hemminki K, Kharazmi E, Ji J, Sundquist K, Fallah M. Multiple
primary (even in situ) melanomas in a patient pose significant risk to family
members. Eur J Cancer. 2014;50(15):2659–67.
31. Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous
melanoma:effects of proband and age. J Invest Dermatol. 2003;120:217–23.
32. Cust AE, Harland M, Makalic E, Schmidt D, Dowty JG, Aitken JF, et al.
Melanoma risk for CDKN2A mutation carriers who are relatives of
population-based case carriers in Australia and the UK. J Med Genet. 2011;
48(4):266–72.
33. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, et al.
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-
based sample. J Natl Cancer Inst. 2005;97(20):1507–15.
34. Robsahm TE, Helsing P, Nilssen Y, Vos L, Rizvi SMH, Akslen LA, et al. High
mortality due to cutaneous melanoma in Norway: a study of prognostic
factors in a nationwide cancer registry. Clin Epidemiol. 2018;10:537–48.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Hemminki et al. Hereditary Cancer in Clinical Practice           (2020) 18:15 Page 6 of 6
